MOTS-C vs Tesamorelin: What 38 Weeks of Running Both Actually Taught Me is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
Last October, a guy named Derek in Scottsdale showed me his DEXA scan at a peptide meetup. He’d been on tesamorelin for 20 weeks. Visceral fat down 31 percent. Fasting insulin barely budged. “I look better but my metabolic panel is still a mess,” he said, holding his phone out like it was a parking ticket he wanted to contest. That conversation crystallized something I’d been thinking about for months: these two peptides get lumped together in metabolic optimization conversations, but they solve fundamentally different problems. I’ve run both, in sequence, under the same prescriber. Here’s the practical comparison.
Compliance frame. MOTS-C is a research-stage mitochondrial-derived peptide not FDA-approved for any human indication. Tesamorelin is FDA-approved under the brand name Egrifta for visceral fat reduction in HIV-infected patients with lipodystrophy, with off-label use in other contexts. Both are accessed in compounded form through 503A pharmacies for individual patient prescriptions based on prescriber clinical judgment. This is not medical advice.
Two Peptides, Two Completely Different Entry Points
Tesamorelin is a growth hormone releasing hormone (GHRH) analog. It binds GHRH receptors on the pituitary, signals growth hormone release, and the metabolic effects (visceral fat reduction being the headline) happen indirectly through increased GH and IGF-1. Top-down hormonal signaling.
MOTS-C is a mitochondrial-encoded peptide that acts directly at the cellular metabolic level. The proposed mechanism centers on mitochondrial function, glucose homeostasis, and metabolic flexibility, none of which routes through the growth hormone axis.
Think of it like this: tesamorelin is remodeling the house by hiring a general contractor (the pituitary) who then subcontracts the work. MOTS-C is more like rewiring the electrical panel yourself. Both can improve the house. The approach, the timeline, and what breaks along the way look nothing alike.
My Numbers Over 38 Combined Weeks
I ran a 26-week tesamorelin protocol followed by a 12-week MOTS-C protocol, separated by about 6 months off. Both under the same physician with consistent lab monitoring. The starting points differed because tesamorelin had already shifted some metrics before I got to MOTS-C, and six months off allowed partial regression.
Tesamorelin (26 weeks)
- Visceral fat: down approximately 39 percent by DEXA
- Total body fat: down 2.4 pounds
- Fasting glucose: 92 to 89
- Fasting insulin: 11.4 to 8.6
- A1C: 5.5 to 5.3
- Triglyceride to HDL ratio: 2.9 to 2.1
- IGF-1: 124 to 198
MOTS-C (12 weeks)
- Visceral fat: small additional reduction, harder to measure precisely at the lower baseline
- Total body fat: down 0.8 percent additional
- Fasting glucose: 96 to 88
- Fasting insulin: 11 to 7.8
- A1C: 5.5 to 5.3
- Triglycerides: 134 to 92
- HDL: 49 to 56
- IGF-1: unchanged
That last line is the tell. MOTS-C left IGF-1 completely flat. It’s not touching the growth hormone axis at all. Whatever it’s doing to glucose and lipids, it’s doing through a different door.
Worth noting: the MOTS-C starting labs were slightly worse than where tesamorelin had left me. Six months off and my metabolic markers drifted back toward pre-tesamorelin territory. Not all the way, but enough to confirm that tesamorelin’s benefits don’t fully persist without ongoing use.
Where the Effects Actually Diverge
The pattern matters more than any individual number.
Tesamorelin’s metabolic improvements were downstream of body composition changes. You lose visceral fat, your insulin sensitivity improves, your lipid ratios get better. The metabolic work is a secondary benefit of the primary structural change.
MOTS-C flipped that relationship. The lipid panel improvements (triglycerides dropping from 134 to 92, HDL climbing from 49 to 56) were the most notable result, and they happened with minimal visible body composition change. Fasting glucose dropping 8 points and insulin dropping over 3 points in just 12 weeks, from a not-terrible starting point, was genuinely surprising.
Subjectively, the experiences were distinct:
Tesamorelin felt like deeper sleep, modest waist circumference reduction at stable bodyweight, and some mild fluid retention in the first few weeks that required a dose adjustment.
MOTS-C was quieter. Slightly better training recovery, no acute energy surge, no visible body recomposition. If I hadn’t pulled labs at 6 and 12 weeks, I might have thought it wasn’t doing much. The labs told a different story.
Here’s my genuinely opinionated take: MOTS-C is the more interesting peptide for people who don’t look metabolically sick but whose bloodwork says otherwise. That’s a huge population. Tesamorelin gets more attention because visceral fat reduction photographs well and the mechanism is well-understood. But for the 45-year-old with a normal BMI, creeping fasting insulin, and triglycerides heading in the wrong direction, MOTS-C might be the smarter first move.
Side Effects: Night and Day
Tesamorelin had a more active side effect profile. Mild injection-site reactions in weeks one through three. One episode of fluid retention that my prescriber caught early and adjusted dosing for. And there’s a real risk of worsened insulin resistance in some patients (didn’t happen to me, but my doctor watched for it at every lab draw).
MOTS-C was essentially invisible on the side effect front. Brief warmth at the injection site. No systemic effects I could detect. No dose adjustments needed. The clean profile is one reason it’s easier to integrate into a routine without the monitoring overhead tesamorelin demands.
Picking the Right One for the Right Problem
Tesamorelin fits when:
- Visceral fat is elevated on DEXA and that’s the primary target
- You’re in a body composition range where significant fat loss potential exists
- You can tolerate close glucose monitoring across the protocol
- Budget allows (tesamorelin costs more, covered below)
MOTS-C fits when:
- Metabolic markers like insulin, glucose, and lipids are the primary concern
- Body composition is already reasonable
- The goal is metabolic flexibility, not dramatic recomposition
- A cleaner side effect profile matters
- Lower cost is a factor
For me, the right sequence turned out to be tesamorelin first (I had visceral fat to lose), then MOTS-C to consolidate the metabolic gains that tesamorelin started but didn’t finish.
What I’d Tell Someone Before They Start Either One
Don’t run both simultaneously. The mechanisms differ but the metabolic effects overlap enough that you can’t attribute results cleanly. My doctor independently said the same thing before I even raised it.
Don’t run either without baseline and follow-up labs. The entire case for both peptides is built on what the numbers do. Without labs, you’re paying for hope.
Don’t skip the basics. Sleep, diet, training, adequate protein. Neither peptide overcomes a crumbling foundation, and anyone who tells you otherwise is selling something.
Don’t rotate frequently. My tesamorelin block was 26 weeks. My MOTS-C block was 12 weeks. Stable protocols with proper monitoring windows produce usable data. Constant switching produces noise.
The Money
- Tesamorelin: roughly $1,420 for a 26-week protocol, all-in (about $55/week)
- MOTS-C: roughly $480 for a 12-week protocol, all-in (about $40/week)
MOTS-C is cheaper on a per-week basis. But cost-effectiveness depends entirely on what you’re solving. If your DEXA shows elevated visceral fat, the tesamorelin spend is justified. If your metabolic panel is the problem and body composition is already in range, MOTS-C is the more efficient investment.
Pharmacy and Sourcing
Both of my protocols were fulfilled through FormBlends and the associated 503A compounding pharmacy network, based on my prescriber’s orders. Lot labeling has been consistent across both peptides. Beyond-use dating clear. Sterility statements available on request.
The pharmacy relationship matters more than any brand name. The reason I trust both protocols is the prescriber and pharmacy infrastructure around them, not a logo on a vial.
What Comes Next
I’m off both peptides currently. The plan is a tesamorelin block of 12 to 16 weeks starting in roughly six months, targeting maintenance of the visceral fat reduction. After that, another 12-week MOTS-C block as a metabolic tune-up.
The framing I’ve settled on: these are tools for specific periods. Not daily supplements. Not permanent protocols. Discrete interventions with measurable outcomes and clear evaluation criteria. Like Derek in Scottsdale eventually figured out, the peptide that fixes what you can see in the mirror and the one that fixes what you can see on a lab report may not be the same peptide. Know which problem you’re solving first.
Compliance disclaimer. MOTS-C is not FDA-approved for any indication. Tesamorelin use outside HIV-associated lipodystrophy is off-label. Both are prescribed by licensed providers and prepared by 503A compounding pharmacies for individual patients based on clinical judgment. This is not medical advice.
Frequently Asked Questions
Can MOTS-C and tesamorelin be stacked together? It’s technically possible, but most prescribers (including mine) advise against it. Running them simultaneously makes it nearly impossible to isolate which peptide is driving which result. Sequential protocols with lab monitoring between blocks give you cleaner data and better decision-making.
Which peptide is better for weight loss specifically? Tesamorelin has stronger evidence and more dramatic effects on visceral fat and body composition. MOTS-C produces modest fat reduction but its primary value is metabolic marker improvement, particularly in glucose, insulin, and lipid panels.
How long does it take to see results from each? Tesamorelin body composition changes typically become measurable on DEXA by 12 to 16 weeks, with continued improvement through 26 weeks. MOTS-C metabolic changes showed up on labs by 6 weeks in my case, with continued improvement at 12 weeks.
Do the benefits of tesamorelin persist after stopping? Partially and temporarily. In my experience, metabolic markers drifted back toward baseline over six months off. This is consistent with clinical data showing visceral fat can reaccumulate after cessation.
Is MOTS-C safe for long-term use? There is no long-term human safety data for MOTS-C. It remains a research-stage peptide. Short-duration protocols (8 to 12 weeks) with lab monitoring are the standard approach among prescribers working with it. My side effect experience was clean, but that’s one data point.
Does tesamorelin affect blood sugar? It can. Tesamorelin has the potential to worsen insulin resistance in some patients through its growth hormone-mediated effects. Close monitoring of fasting glucose and insulin is standard protocol. In my case, glucose and insulin both improved, but the risk is documented and real.
What labs should I get before starting either peptide? At minimum: fasting glucose, fasting insulin, A1C, comprehensive lipid panel (including triglycerides and HDL), IGF-1, and a DEXA scan if body composition is part of the assessment. Repeat at midpoint and end of protocol. Without this data, you’re guessing.
